Tarlox and Sotorasib in Patients With KRAS G12C Mutations
A Phase Ib / II Trial of Tarloxotinib and Sotorasib in Patients With KRAS G12C Mutations
Sponsor: Medical University of South Carolina
Terminated
Study drug was discontinued by manufacturer for business reasons.
Other terminated trials from Medical University of South Carolina
- Breast Cancer · Phase PHASE4 · Feb 2026
- Bleeding Esophageal Varices · Phase PHASE4 · Dec 2024
- Prostate Cancer · Phase PHASE2 · Aug 2024
- Intrathecal Morphine · Phase PHASE4 · May 2024
- Blood Pressure · Phase NA · Feb 2024
See all terminations from Medical University of South Carolina
Other Non-Small Cell Lung Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Medical University of South Carolina leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Jan 2026 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Aug 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Feb 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical University of South Carolina
- Rain Oncology Inc
For direct contact, visit the study record on ClinicalTrials.gov .